Deconstructing the molecular portrait of basal-like breast cancer

Trends in Molecular Medicine

Volumn 12, Issue 11, 2006, Pages 537-544

  Yehiely, Fruma ^a   Moyano, Jose V ^a   Evans, Joseph R ^a   Nielsen, Torsten O ^b   Cryns, Vincent L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; ANTINEOPLASTIC AGENT; BETA4 INTEGRIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; LAMININ ALPHA3; LAMININ GAMMA2; MATRIX METALLOPROTEINASE 14; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B BETA; PROTEIN KINASE FYN; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER INCIDENCE; CELL HETEROGENEITY; CLINICAL TRIAL; DNA STRAND BREAKAGE; EXPERIMENTAL MOUSE; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOTE; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; NONHUMAN; ONCOGENE NEU; POSTOPERATIVE CARE; PROGNOSIS; REVIEW; X CHROMOSOME ABERRATION;

BETA-CRYSTALLIN A CHAIN; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, BASAL CELL; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 33750976943     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.09.004     Document Type: Review

References (80)

1. Perou C.M., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
2. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10869-10874
3. Sorlie T., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8418-8423
4. Sotiriou C., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10393-10398
5. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
6. Dairkee S.H., et al. Monoclonal marker that predicts early recurrence of breast cancer. Lancet 1 (1987) 514
7. Wilhelmsen K., et al. Multiple functions of the integrin α6β4 in epidermal homeostasis and tumorigenesis. Mol. Cell. Biol. 26 (2006) 2877-2886
8. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
9. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
10. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
11. Mariotti A., et al. EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J. Cell Biol. 155 (2001) 447-458
12. Bowden E.T., et al. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J. Biol. Chem. 277 (2002) 35862-35868
13. Moyano J.V., et al. αB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest. 116 (2006) 261-270
14. Moscova M., et al. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res. 66 (2006) 1376-1383
15. Wang D., et al. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene 19 (2000) 4647-4659
16. Dumont N., and Arteaga C.L. Targeting the TGFβ signaling network in human neoplasia. Cancer Cell 3 (2003) 531-536
17. Koshikawa N., et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 148 (2000) 615-624
18. Kao Y.R., et al. Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin. Cancer Res. 9 (2003) 2807-2816
19. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103-112
20. Stingl J., et al. Purification and unique properties of mammary epithelial stem cells. Nature 439 (2006) 993-997
21. Domen J., and Weissman I.L. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. J. Exp. Med. 192 (2000) 1707-1718
22. Zhang C.C., et al. Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2184-2189
23. Nielsen T.O., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10 (2004) 5367-5374
24. Abd El-Rehim D.M., et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 203 (2004) 661-671
25. Potemski P., et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69 (2005) 478-485
26. Carey L.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
27. Tsuda H., et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol. 24 (2000) 197-202
28. Livasy C.A., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 19 (2006) 264-271
29. Rodriguez-Pinilla S.M., et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res. 12 (2006) 1533-1539
30. Fulford L.G., et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49 (2006) 22-34
31. Jacquemier J., et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J. Pathol. 207 (2005) 260-268
32. Reis-Filho J.S., et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 49 (2006) 10-21
33. Jones C., et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin. Cancer Res. 10 (2004) 5988-5997
34. Bocker W., et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab. Invest. 82 (2002) 737-746
35. Turner N., et al. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4 (2004) 814-819
36. Scully R., and Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408 (2000) 429-432
37. Ganesan S., et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111 (2002) 393-405
38. Xu X., et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22 (1999) 37-43
39. Hedenfalk I., et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344 (2001) 539-548
40. Lakhani S.R., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20 (2002) 2310-2318
41. +) phenotype of BRCA1-related breast cancer. Cancer Res. 64 (2004) 830-835
42. Crook T., et al. p53 mutations in BRCA1-associated familial breast cancer. Lancet 350 (1997) 638-639
43. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349 (1997) 1505-1510
44. Foulkes W.D., et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98 (2003) 1569-1577
45. Richardson A.L., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9 (2006) 121-132
46. Futreal P.A., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (1994) 120-122
47. Catteau A., et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 (1999) 1957-1965
48. Wei M., et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 65 (2005) 10692-10699
49. Beger C., et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 130-135
50. Garcia-Higuera I., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7 (2001) 249-262
51. Taniguchi T., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9 (2003) 568-574
52. van der Heijden M.S., et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 63 (2003) 2585-2588
53. Sainsbury J.R., et al. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1 (1987) 1398-1402
54. Porter P.L., et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3 (1997) 222-225
55. Keyomarsi K., et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347 (2002) 1566-1575
56. Chelouche-Lev D., et al. αB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 100 (2004) 2543-2548
57. Clark J.I., and Muchowski P.J. Small heat-shock proteins and their potential role in human disease. Curr. Opin. Struct. Biol. 10 (2000) 52-59
58. Kamradt M.C., et al. The small heat shock protein αB-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J. Biol. Chem. 276 (2001) 16059-16063
59. Kamradt M.C., et al. The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J. Biol. Chem. 280 (2005) 11059-11066
60. Debnath J., and Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 5 (2005) 675-688
61. Dontu G., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17 (2003) 1253-1270
62. Shackleton M., et al. Generation of a functional mammary gland from a single stem cell. Nature 439 (2006) 84-88
63. Pardal R., et al. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3 (2003) 895-902
64. Al-Hajj M., et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3983-3988
65. Ponti D., et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65 (2005) 5506-5511
66. Dontu G., et al. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15 (2004) 193-197
67. Foulkes W.D. BRCA1 functions as a breast stem cell regulator. J. Med. Genet. 41 (2004) 1-5
68. Saal L.H., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65 (2005) 2554-2559
69. Elenbaas B., et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15 (2001) 50-65
70. Xiong J., et al. BRCA1 inhibition of telomerase activity in cultured cells. Mol. Cell. Biol. 23 (2003) 8668-8690
71. Rouzier R., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11 (2005) 5678-5685
72. Goffin J.R., et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97 (2003) 527-536
73. Robson M.E., et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6 (2004) R8-R17
74. Banerjee S., et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 59 (2006) 729-735
75. Reis-Filho J., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 209 (2006) 445-453
76. Quinn J.E., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63 (2003) 6221-6228
77. Tassone P., et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88 (2003) 1285-1291
78. Farmer H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
79. Taylor D.R., and Hooper N.M. The prion protein and lipid rafts. Mol. Membr. Biol. 23 (2006) 89-99
80. Miki Y., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71